
    
      GC is the second most common cause of cancer-related deaths worldwide. Most patients are
      diagnosed with unresectable advanced or metastatic stage disease losing the radical surgery
      opportunity. Till now there is no novel targeted drug which can increase the OS for advanced
      GC patients except HER-2 positive patients.

      Approximate 30 patients with unresectable GC treated with 4 cycles chemotherapy and valued as
      stable disease will be enrolled in this study,The investigators will evaluate the efficacy
      and security of apatinib and S-1 as maintenance therapy.
    
  